August 2016

Newsletter-Banner

ACT-AD Welcomes New Science Advisory Board Member

ACT-AD is proud to announce Phyllis Greenberger, M.S.W., as the newest member of our Science Advisory Board. Greenberger is the past president and CEO of the society for Women’s Health Research and a women’s health consultant. Through her leadership, dedication, and promotion of women’s health, sex differences are now widely known and recognized as a critical factor in women’s health. For a more complete bio, please go here.

National Survey Results Highlight Dementia Priorities

A study funded by the Retirement Research Foundation surveyed Americans with “personal and professional experience with dementia.” The survey gathered opinions on what people view as their most important priorities. To read the full summary of the survey, please go here.

Study Finds Dementia Patients with Low Continuity of Care Have Higher Health Costs

A recent study published in JAMA Internal Medicine found that dementia patients with a low continuity of care often have higher overall health care costs. “When considering differences in health care spending per beneficiary, individuals with the most fragmented care are associated with an additional $567 million to $1.1 billion in health care spending compared with those with medium or high continuity,” the study found. Read the full study here.

ACT-AD’s Bens Presents at August PDUFA VI Public Meeting

ACT-AD Executive Director Cynthia A. Bens spoke at the U.S. Food and Drug Administration’s (FDA) August 15 public meeting focused on the upcoming reauthorization of the Prescription Drug User Fee Act (PDUFA). Bens participated on two panels: Pre-Market Review and Post-Market Safety and Administrative Enhancements: Hiring, IT, and Financial. To read Bens’ full comments, please go here. On August 22, formal feedback was submitted to the FDA on pre-market review, FDA hiring, enhancements to patient-focused drug development, benefit-risk assessment, utilization of real-world evidence, advancing model informed drug development and innovative clinical trial designs. To view these comments, go here.

NIH Creates Bypass Budget to Meet National Alzheimer’s Plan

The National Institutes of Health (NIH) created a bypass budget to estimate the amount of funding needed to meet the goals of the National Plan to Address Alzheimer’s Disease and treat dementia by 2025. The NIH’s Bypass Budget Alzheimer’s Disease and Related Dementias for Fiscal Year 2018 was released on August 1, 2016. The budget and accompanying materials can be found here.

Save the Date for ACT-AD’s Ninth Annual FDA/AD Allies Meeting/November 16

Mark your calendars! ACT-AD’s Ninth Annual FDA/AD Allies Meeting is set for Wednesday, November 16, 2016, at the Bethesda North Marriott Hotel and Conference Center (5701 Marinelli Road, North Bethesda, Maryland, 20852). Get more information here.